Clinical trial NCT03089879: A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
Official title: A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Dysentery, Bacillary
Keywords: Immunogenicity, Vaccine
Immunologic Memory
GMMA
Shigella Vaccines
Shigellosis
Dysentery, Bacillary
Healthy Volunteers
Safety
Bacteria
Clinical Trials, Phase 1
Shigella sonnei
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2017-03-24
Enrollment: 35
Sex: ALL
Minimum age (years): 22
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: GVGH Shigella Sonnei 1970GAHB is a vaccine aimed at preventing the disease caused by Shigella sonnei.

A post-hoc analysis of subjects who participated in the parent study showed significantly different responses in subjects with detectable versus undetectable antibody titres at baseline, suggesting the possibility that the vaccine might not be sufficiently immunogenic in completely naïve adults.

This study was then designed to further characterize the immunogenicity profile of the vaccine and to evaluate whether it was able to induce an immunological memory response.


Eligibility criteria: Inclusion Criteria:

* Males and females, aged 22 to 50 years, who were previously vaccinated, with either vaccine (3 doses) or placebo, in H03_01TP and who had undetectable antibody titers at baseline, or Males and females, aged 22 to 50 years, who were not part of H03_01TP.
* Individuals who, after the nature of the study has been explained to them, and prior to any protocol specific procedures being performed, have given written consent according to local regulatory requirements.
* Individuals in good health as determined by the outcome of medical history, physical examination, hematological blood tests and clinical judgment of the investigator.
* If women of child-bearing potential, have a negative urinary pregnancy test prior study vaccination and willingness to use acceptable birth control measures for the entire study duration.
* Individuals affiliated to a social security regimen.

Exclusion Criteria:

* Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
* Individuals with any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
* Individuals who are not able to understand and to follow all required study procedures for the whole period of the study.
* Individuals with known hepatitis B or C or suspected HIV infection or HIV related disease with history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system.
* Progressive, unstable or uncontrolled clinical conditions.
* Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
* Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
* Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
* Abnormal function of the immune system resulting from:

  * Clinical conditions;
  * Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to informed consent;
* Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
* Received immunoglobulins or any blood products within 180 days prior to informed consent.
* Study personnel as an immediate family or household member.
* Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
* Individuals who have received an investigational product in another clinical trial 28 days prior to first study visit or intent to receive another investigational product at any time during the conduct of this study.
* Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within the entire study duration. Inactivated influenza vaccine can be given, but only 4 weeks earlier or 4 weeks later than the date of immunization.
* Individuals who have received blood, blood products, and/or plasma derivatives including parenteral immunoglobulin preparations in the past 180 days.
* Individuals with body temperature \> 38.0 degrees Celsius within 3 days of intended study vaccination.
* Individuals with Body Mass Index \> 30 kg/m2.
* Individuals with history of substance or alcohol abuse within the past 2 years.
* Women who are pregnant or are breast-feeding, or are of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.
* Females with history of stillbirth, neonatal loss, or previous infant with anomaly.
* Individuals who have a previously laboratory confirmed or suspected disease caused by S. sonnei.
* Individuals who have had household contact with/and or intimate exposure to an individual with laboratory confirmed S. sonnei.
* Any condition, which, in the opinion of the investigator may pose an increased and unreasonable safety risk to the subject if participating to the present study.
* Individuals with a neutrophil count value lower than 1.8 10\^9/L at screening assessment.
* Individuals with human leukocyte antigen (HLA)-B27 positive and/or with history of reactive arthritis.
* Previous history of Benign Ethnic Neutropenia or drug related Neutropenia and/or concomitant treatment with neutropenic agents.

Primary outcomes:
measure: Concentrations of Immunoglobulin (IgG) Against Lipopolysaccharide (LPS) S. Sonnei O-antigen
timeFrame: At Day 8 (7 days after vaccination)
Secondary outcomes:
measure: Number of Subjects With Abnormal Haematological Test Values
timeFrame: At Day 8 (7 days after vaccination) and Day 85 (84 days after vaccination)
measure: Number of Subjects With Solicited Local Adverse Events
timeFrame: From 30 minutes through Day 7 post-vaccination
measure: Number of Subjects With Solicited Systemic Adverse Events
timeFrame: From 30 minutes through Day 7 post-vaccination
measure: Number of Subjects With Unsolicited Adverse Events
timeFrame: Throughout the study period (From Day 1 up to Day 85)
measure: Number of Subjects With Serious Adverse Events (SAEs)
timeFrame: Throughout the study period (from Day 1 up to Day 85)
measure: Concentrations of IgG Against LPS S. Sonnei O-antigen
timeFrame: At Days 15, 29 and 85 (14, 28 and 84 days after vaccination)
measure: Anti-LPS S. Sonnei IgG Geometric Mean Ratios
timeFrame: At Days 8, 15, 29 and 85 (7, 14, 28 and 84 days after vaccination)
measure: Percentage of Subjects With Seroresponse for Anti-LPS S. Sonnei
timeFrame: At Days 8, 15, 29 and 85 (7, 14, 28 and 84 days after vaccination)
measure: Percentage of Subjects With Anti-LPS S. Sonnei Concentrations Equal to or Above (≥) 121 EU/mL
timeFrame: At Days 8, 15, 29 and 85 (7, 14, 28 and 84 days after vaccination)
Other outcomes:
Locations:
city: Paris
country: France
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Launay O, Ndiaye AGW, Conti V, Loulergue P, Scire AS, Landre AM, Ferruzzi P, Nedjaai N, Schutte LD, Auerbach J, Marchetti E, Saul A, Martin LB, Podda A. Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial. Front Immunol. 2019 Mar 8;10:335. doi: 10.3389/fimmu.2019.00335. eCollection 2019.
citation: Micoli F, Rossi O, Conti V, Launay O, Scire AS, Aruta MG, Nakakana UN, Marchetti E, Rappuoli R, Saul A, Martin LB, Necchi F, Podda A. Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension. Front Immunol. 2021 May 4;12:671325. doi: 10.3389/fimmu.2021.671325. eCollection 2021.